Effects of Pelvic Floor Training in Male Chronic Pelvic Pain, Correlation Between Subjective and Objective Outcomes

Long Term Effects of Pelvic Floor Re-education in Men With Chronic Pelvic Pain, Using Bio-feedback and Home Training - Subjective Outcomes in Correlation to Objective Measurements of the Lower Urinary Tract and Pelvic Floor

The goal of this randomized controlled study is to establish the long-term effect of pelvic floor re-education using biofeedback and home training for men with chronic pelvic pain. The main questions it aims to answer are if pelvic floor re-education using bio-feedback and home training will give a long-lasting improvement in symptoms, assessed with a validated symptom score (the National Institute of Health - Chronic Prostatitis Symptom Index) and if an improvement in symptoms can be correlated to objective measurements of pelvic floor function. Participants will be asked to do pelvic floor exercises daily during six months with additional sessions of bio-feedback training. The control group will have no changes in their on-going treatment for their chronic pelvic pain and will be offered to enter the treatment group after six months.

Study Overview

• Status: Recruiting
• Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome; Chronic Prostatitis; Chronic Pelvic Pain Syndrome; Pelvic Floor; Relaxation
• Intervention / Treatment: Other: Pelvic floor re-education using bio-feedback and home training

Detailed Description

At baseline all included study subjects will fill in a validated symptom score, the National Institute of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) and have an assessment of their pelvic floor muscles and undergo a urodynamic evaluation.

The intervention group will perform short daily session of pelvic floor muscle training at home during six months in combination with four bio-feedback sessions during the first months. The study subjects will receive an individual instruction based on the pelvic floor assessment from the baseline visit. The study subjects will report their training in a digital diary.

A reevaluation will be done at three, six and twelve months. At six and 12 months repeating the baseline tests. At three months a renewed assessment of muscle function and the NIH-CPSI questionnaire.

The control group will be instructed not to engage in any new treatment for their chronic pelvic pain during the study period. After the six months evaluation all participants in the control group will be offered to be enrolled in the treatment group, with the same set-up and follow-up as the treatment group.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lotta Renström Koskela, M.D; Phone Number: +46-8-12370000; Email: lotta.renstrom-koskela@regionstockholm.se

Study Locations

• Sweden
  • Stockholm, Sweden, 141 86
    • Recruiting
    • Karolinska university Hospital
    • Contact: Lotta R Koskela, MD; Phone Number: +46724694888; Email: lotta.renstrom-koskela@sll.se

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Men over the age of 18, residents in Sweden, diagnosed with Chronic Primary Pelvic Pain Syndrome (CPPPS) according to the International Statistical Classification of Diseases and Related Health Problems (ICD-10) (N41.1 (chronic prostatitis), N41.9 (Inflammatory disease of prostate, unspecified), N50.8F (Chronic Pelvic Pain Syndrome in men)

Exclusion Criteria:

• Cancer in the abdomen or pelvic organs (current or previous)
• Congenital anomalies affecting the pelvic region (Bladder exstrophy, Myelomeningocele etc.)
• Transsexual male, (i.e. at birth biologically female)
• Diseases affecting the nerve function to the pelvic and/or lower extremities, other disease or ongoing treatment that could have an impact on the outcome of the study.
• Incapability to participate in testing or follow training instructions due to mental incapacity, language difficulties etc.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pelvic floor muscle re-education; Intervention with pelvic floor re-education using bio-feedback and home training for 6 months, with a follow up visit after an additional period of 6 months	Other: Pelvic floor re-education using bio-feedback and home training; Pelvic floor re-education using bio-feedback and home training
No Intervention: Standard Care; No intervention during 6 months after inclusion. After the 6 month follow-up evaluation the study subjects are offered to participate in the interventional arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in symptom score on the National Institute of Health-Chronic Prostatitis Symptom Index questionnaire	Change in total score, range from 0-43 points. Higher score indicates worse symptoms.	Measured 3, 6 and 12 months after inclusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in sub score on the National Institute of Health-Chronic Prostatitis Symptom Index questionnaire	Sub score according to the domains; pain 0-21, urological symptoms 0-10 points and quality of life impact 0-12 points. Higher score indicates worse symptoms in all three domains.	Measured 3, 6 and 12 months after inclusion
Changes in global voiding function using free flow non-invasive urodynamic testing	Changes in global voiding function using free flow non-invasive urodynamic testing with electromyogram. Global assessment where combined results from maximum urinary flow rate, voided volume, post voiding residual volume, pelvic floor activity during voiding and the shape of the curve are used to define types of voiding patterns.; Normal flow; Asymmetrical obstructive flow; Symmetrical low flow; Irregular curve, straining flow; Plateau low flow As described in the International Continence Society good urodynamic practices recommendations 2018 and Urodynamics (third edition) by P. Abrams.	Measured 6 and 12 months after inclusion
Changes in global storing function of the bladder using invasive urodynamics, cystometry	Changes in global bladder function using invasive urodynamics with cystometry with electromyogram. Global assessment where combined results from sensory input, cystometric capacity, detrusor activity, compliance and pelvic floor activity are combined to define different patterns.; Normal cystometry; Abnormal sensory input; Detrusor activity; Abnormal compliance; Abnormal bladder capacity As described in the International Continence Society good urodynamic practices recommendations 2018 and Urodynamics (third edition) by P. Abrams.	Measured 6 and 12 months after inclusion
Changes in global voiding function using invasive urodynamics, pressure-flow study	Changes in global voiding function using invasive urodynamics, pressure-flow study with electromyogram. Global assessment where combined results from detrusor contractility, urinary flow and pelvic floor activity are combined to define different patterns.; Normal flow; Under-active flow; Obstructed flow As described in the International Continence Society good urodynamic practices recommendations 2018 and Urodynamics (third edition) by P. Abrams.	Measured 6 and 12 months after inclusion
Changes in urethral pressure using invasive urodynamics, urethral pressure profile	Changes in urethral pressure using invasive urodynamics, urethral pressure profile.; Maximum urethral pressure (cmH2O); Maximum urethral closure pressure (cmH2O) As described in Urodynamics (third edition) by P. Abrams.	Measured 6 and 12 months after inclusion
Changes in pelvic floor muscle assessment according to test specifics by Frawley et al 2021 and the modified Oxford Scale according to Laycock et al 2001.	Pelvic floor muscle assessment according to test specifics by Frawley et al 2021; Assessment of muscle tone- Decreased / normal / increased; Assessment of voluntary contraction- No contraction / correct contraction / contraction only with help from other muscles / uncertain / straining; Assessment of relaxation post contraction- Yes / partial or delayed / no; Assessment of tendernessYes / NoIf yes location is noted and severity of pain is graded according to numeric rating scale, 0-10, with higher value indicatinge more severe pain. Modified Oxford Scale for assessment of pelvic floor muscle power, graded from 0-5 with higer value indicating stronger power.	Measured 3, 6 and 12 months after inclusion
Correlation between subjective and objective measurements	Correlation between subjective measurements using the National Institute of Health-Chronic Prostatitis Symptom Index questionnaire and objective findings on urodynamic testing and pelvic floor assessment.	Measured 3, 6 and 12 months after inclusion

Collaborators and Investigators

• Sponsor: Region Stockholm
• Collaborators: Karolinska Institutet
• Investigators: Principal Investigator: Lotta Renström Koskela, M.D, Karolinska university Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2023
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: October 17, 2023
• First Submitted That Met QC Criteria: October 30, 2023
• First Posted (Actual): November 2, 2023

Study Record Updates

• Last Update Posted (Actual): April 16, 2024
• Last Update Submitted That Met QC Criteria: April 12, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Urodynamics; Physiotherapy; Chronic pelvic pain syndrome; Pelvic floor muscles; Chronic prostatitis; Chronic prostatitis with chronic pelvic pain syndrome; Bio-feedback
• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Pain; Neurologic Manifestations; Disease Attributes; Disease; Prostatic Diseases; Urogenital Diseases; Male Urogenital Diseases; Genital Diseases, Male; Genital Diseases; Syndrome; Chronic Disease; Somatoform Disorders; Pelvic Pain; Prostatitis
• Other Study ID Numbers: K 2023-4671

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No